Company has nearly tripled its cash balance in a week.
Sanofi will pay Adagene $17.5 million up front.
Biden said the U.S. government had invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
| Website: | www.sanofi.com |
| Email: | IR@sanofi.com |
| Main Phone: | +33 153774000 |
| Address: | 54, Rue La Boetie |
| City / Town: | Paris |
| Country: | FR |
| Postal Code: | 75008 |
| Exchange: | NGS |
| CEO: | Paul Hudson |
| Employees: | 99412 |
| Issuer Type: | CS - Common Stock |
| Sector/Industry: | Healthcare |
Company has nearly tripled its cash balance in a week.
Sanofi will pay Adagene $17.5 million up front.
Biden said the U.S. government had invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.
U.S. District Judge Dean Ochiai in Honolulu ruled that the companies failed to change the drug’s label to warn non-white patients of health risks from the blood thinner despite knowing some of the risks for more than a decade.
Initial doses are scarce and rationed, and shots for health workers and nursing home residents are expected to begin in the coming days.
The promise to play by established rules underlines a highly politicized debate over what action is needed to rein in COVID-19 quickly and to jumpstart global business and trade.
Principia is targeting immune-mediated diseases with lead programs in pemphigus and multiple sclerosis.
The award is the biggest yet from ‘Operation Warp Speed,’ the White House initiative aimed at accelerating access to vaccines and treatments to fight COVID-19.
A new $1 billion fund backed by 20 drugmakers including Merck and Pfizer is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
The company expects to begin mid-stage trials in the US in mid-summer.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
